Preventing antimalarial drug resistance through combinations

Drug Resistance Updates

Volumn 1, Issue 1, 1998, Pages 3-9

  White, N J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949810315     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80208-2     Document Type: Article

References (50)

1. Winstanley P., and Breckenridge A. Therapeutics and drug development. Lancet 349 Suppl. 3 (1997) 3-4
2. Grosset J. Bacteriological basis of short course chemotherapy for tuberculosis. Clin Chest Med 1 (1980) 231-234
3. White N.J., and Olliaro P.L. Rationale for combination therapy for malaria. Parasitol Today 12 (1996) 399-401
4. Peters W. Chemotherapy and Drug Resistance in Malaria. 2nd Edn. (1987), Academic Press, London
5. Watkins W.M., Brandling B.A., Nevill C.G., et al. Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Trans R Soc Trop Med Hyg 82 (1988) 398-403
6. Canfield C.J., Pudney M., and Gutteridge W.E. Interaction of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 80 (1995) 373-381
7. Peterson D.S., Walliker D., and Wellems T.E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85 (1988) 9114-9118
8. Foote S.J., Galatis D., and Cowman A.F. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 87 (1990) 3014-3017
9. Peterson D.S., Milhous W.K., and Wellems T.E. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87 (1990) 3018-3022
10. Peterson D.S., Di Santi S.M., Povoa M., Calvosa V.S., do Rosario V.E., and Wellems T.E. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am J Trop Med Hyg 45 (1991) 492-497
11. Field J.W., and Edeson J.F.B. Paludrine resistant falciparum malaria. Trans R Soc Trop Med Hyg 43 (1949) 233-236
12. Burgess R.W., and Young M.D. The development of resistance by Plasmodium falciparum. Bull World Health Organ 20 (1959) 37-46
13. Thaithong S., Chan S.W., Songsomboon S., et al. Pyrimethamine resistant mutations in Plasmodium falciparum. Mol Biochem Parasitol 52 (1992) 149-157
14. Foote S.J., and Cowman A.F. The mode of action and the mechanism of resistance to antimalarial drugs. Acta Tropica 56 (1994) 157-171
15. Cowman A.F., Galatis D., and Thompson J.K. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr I gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA 91 (1994) 1143-1147
16. Foote S.J., Thompson J.K., Cowman A.F., and Kemp D.J. Amplification of the multidrug resistance gene in some chloroquinine-resistant isolates of P. falciparum. Cell 57 (1989) 921-930
17. Wellems T.E., Panton L.J., Gluzman I.Y., do Rosario V.E., Gwadz R.W., and Walker-Jonah A. Chloroquinine resistance not linked to mdr-like genes in Plasmodium falciparum cross. Nature 345 (1990) 253-255
18. Wilson C.M., Volkman S.K., Thaithong S., et al. Amplification of pfmdr I associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol Biochem Parasitol 57 (1993) 151-160
19. Bray P.G., and Ward S.A. Malaria chemotherapy: resistance to quinoline containing drugs in Plasmodium falciparum. FEMS Microbiol Lett 113 (1993) 1-7
20. White N.J. Assessment of the pharmacodynamic properties of the antimalarial drugs in vivo. Antimicrob Agents Chemother 41 (1997) 1413-1422
21. In press. Paul R., Hackford I., Brockman A., Muller-Graf C., Price R., Luxemburger C., White N.J., Nosten F., and Day K.P. Transmission intensity and Plasmodium falciparum diversity in Shoklo camp on the Thai-Burmese border. Am J Trop Med Hyg (1998)
22. Babiker H.A., and Walliker D. Current views on the population structure of Plasmodium falciparum: implications for control. Parasitol Today 13 (1997) 262-267
23. Lipsitch M., and Levin B.R. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41 (1997) 363-373
24. Price R.N., Nosten F., Luxemburger C., ter Kuile F., Paiphun L., Chongsuphajaisiddhi T., and White N.J. The effects of artemisinin derivatives on malaria transmissability. Lancet 347 (1996) 1654-1658
25. Watkins W.M., and Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87 (1993) 75-78
26. White N.J. Combination treatment for falciparum prophylaxis. Lancet 1 (1987) 680-681
27. Palmer K.J., Holliday S.M., and Brogden R.N. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 45 (1993) 430-475
28. Krishna S., and White N.J. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin Pharmacokinet 30 (1996) 263-299
29. in press. Austin D.J., White N.J., and Anderson R.M. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theoret Biol (1998)
30. Peters W. The prevention of antimalarial drug resistance. Pharmacol Ther 47 (1990) 499-508
31. Peters W., and Robinson B.L. The chemotherapy of rodent malaria XXXV: further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'. Ann Trop Med Parasitol 78 (1984) 459-466
32. Chawira A.N., Warhurst D.C., Robinson B.L., and Peters W. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. Trans R Soc Trop Med Hyg 81 (1987) 554-558
33. Tin F., Hlaing N., Tun T., Win S., and Lasserre R. Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma. Bull World Health Organ 63 (1985) 727-730
34. Meek S.R., Doberstyn E.B., Gauzere B.A., Thanapanich C., Nordlander E., and Phuphaisan S. Treatment of falciparum malaria with quinine and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai-Kampuchean border. Am J Trop Med Hyg 35 (1986) 246-250
35. Rieckmann K., Suebsaeng L., and Rooney W. Response of Plasmodium falciparum infections to pyrimethamine-sulfadoxine in Thailand. Am J Trop Med Hyg 37 (1987) 211-216
36. Nosten F., ter Kuile F., Chongsuphajaisiddhi T., et al. Mefloquineresistant falciparum malaria on the Thai-Burmese border. Lancet 337 (1991) 1140-1143
37. White N.J. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 30 (1992) 571-585
38. Looareesuwan S., Viravan C., Vanijanonta S., et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet 339 (1992) 821-824
39. Nosten F., Luxemburger C., ter Kuile F.O., Woodrow C., Pa Eh J., Chongsuphajaisiddhi T., and White N.J. Treatment of multi-drug resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 170 (1994) 971-977
40. ter Kuile F., Nosten F., Thieren M., et al. High dose mefloquine in the treatment of multidrug resistant falciparum malaria. J Infect Dis 166 (1992) 1393-1400
41. Smithuis F.M., van Woensel J.B., Nordlander E., Vantha W.S., and ter Kuile F.O. Comparison of two mefloquine regimens for treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border. Antimicrob Agents Chemother 37 (1993) 1977-1981
42. Price R.N., Nosten F., Luxemburger C., van Vugt M., Paiphun L., Chongsuphajaisiddhi T., and White N.J. Artesunate-mefloquine treatment of 1967 patients with multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 91 (1997) 574-577
43. ter Kuile F., Luxemburger C., Nosten F., Phaipun L., Chongsuphajaisiddhi T., and White N.J. Predictors of mefloquine treatment failure: a prospective study in 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 89 (1995) 660-664
44. Fontanet A.L., and Walker A.M. Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand. Am J Trop Med Hyg 49 (1993) 465-472
45. Looareesuwan S., Viravan C., Webster H.K., Kyle D.E., Hutchinson D.B., and Canfield C.J. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54 (1996) 62-66
46. Martin D.C., and Arnold J. The effect of parasite population on the curative action of pyrimethamine. Trans R Soc Trop Med Hyg 62 (1968) 379-384
47. Cox F.E., and Millott S.M. The importance of parasite load in the killing of Plasmodium vinckei in mice treated with Corynebacterium parvum or alloxan monohydrate. Parasitology 89 (1984) 417-424
48. Onyiorah E., van Hensbroek M.B., Jah M.S., and Greenwood B. Early clinical failures after pyrimethamine-sulfadoxine treatment of uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 90 (1996) 307-308
49. Bloland P.B., Lackritz E.M., Kazembe P.N., Were J.B., Steketee R., and Campbell C.C. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 167 (1993) 932-937
50. Sudre P., Breman J.G., McFarland D., and Koplan J.P. Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis. Int J Epidemiol 21 (1992) 146-154